Clinical trials: Functional Performance
- Condition Functional Performance
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Multiple Sclerosis
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
The primary objective is to evaluate the feasibility of the Multiple Sclerosis Performance Test (MSPT) in a clinical care setting when used by participants with Multiple Sclerosis (MS).
- Trial name
- NCT03926637
- Testing
- Multiple Sclerosis Performance Test (MSPT)
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 3,073 people
- Sponsor
- Biogen
Visual Functions
Prospective Clinical Trials to Assess Performance and Safety of EyeSwift Pro
EyeSwift Pro assessment of visual function parameters as measured by psychophysics
- Trial name
- NCT05382676
- Testing
- Eyeswift Pro
- Volunteers
- 500 people
- Sponsor
- NovaSight
Multiple Sclerosis
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Study assessing cognitive function and physical activity in people with relapsing remitting multiple sclerosis.
- Trial name
- CogniPlus (NCT01491100)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 17 sites in Albania, Algeria and 15 more
- Volunteers
- 1,085 people
- Sponsor
- Bayer
Muscular Dystrophies, Muscular Dystrophy, Duchenne
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD).
- Conditions
- Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- HOPE-2 (NCT03406780)
- Testing
- CAP-1002
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Capricor Inc.
Limb-girdle Muscular Dystrophy
A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy…
- Trial name
- NCT04475926
- Where
- 26 sites in United States, Belgium and 8 more
- Volunteers
- 205 people
- Sponsor
- Sarepta Therapeutics, Inc.
Chronic Functional Constipation
Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months
The study is aimed at the efficacy and safety evalutation of the study treatments through a 2-weeks study period and the subsequent follow-up-
- Trial name
- NCT02751411
- Testing
- micro-enema with Promelaxin, Macrogol 4000
- Where
- 4 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Aboca Spa Societa' Agricola
Single Ventricle Heart Disease
Fontan Udenafil Exercise Longitudinal Assessment Trial
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent subjects who have undergone the Fontan…
- Trial name
- FUEL (NCT02741115)
- Testing
- Udenafil
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 400 people
- Sponsor
- Mezzion Pharma Co. Ltd
Single Ventricle Heart Disease After Fontan Surgery
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic measures of exercise capacity, ventricular…
- Trial name
- NCT02201342
- Testing
- Udenafil
- Where
- 6 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Mezzion Pharma Co. Ltd